Drugs / UZATRESGENE AUTOLEUCEL
UZATRESGENE AUTOLEUCEL
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04044859 | Aug 2019 → Dec 2026 expected | endometrial cancer, esophageal cancer, gastric cancer, gastroesophageal cancer +5 | USWM CT, LLC | Active not recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04752358 | Sep 2021 → Jun 2023 | esophageal cancer, gastroesophageal cancer | Adaptimmune | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | UZATRESGENE AUTOLEUCEL | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068465 ↗ |
| Known as | ADP-A2M4CD8 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04752358 ↗ |
| Known as | Uzatresgen autoleucel | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068465 ↗ |
| Modality | Cell therapy | “ADP-A2M4CD8 T-cell therapy” NCT04044859 ↗ |
| Route | Other | “Infusion of autologous genetically modified ADP-A2M4CD8 on Day 1” NCT04044859 ↗ |